Overview

A Prospective, Open-label, Multi Cohort Clinical Study on the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma With Camrelizumab Combined With Chemotherapy

Status:
Not yet recruiting

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

This is a randomized, open, parallel controlled clinical study. Patients with advanced esophageal cancer who have not received any previous systemic antitumor therapy for esophageal cancer were selected to compare the efficacy and safety of carrilizumab combined with chemoradiotherapy versus carrilizumab combined with chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Cancer Hospital

Treatments:

Paclitaxel